Adrenal Insufficiency

Roberto Salvatori, MD

CASE PRESENTATION

A 44-year-old woman whose medical history was remarkable only for chondrocalcinosis of the knees was referred to the endocrinology department to exclude a metabolic or hormonal problem. The patient complained of several weeks of fatigue, somnolence, pain in the large joints, nausea, and decreased appetite. Her symptoms had appeared gradually, without a clear precipitating event. She had also noted an unintentional 11-kg weight loss over a period of 6 months. She had a remote history of amenorrhea, but she was presently menstruating regularly. She was taking no medications, with the exception of acetaminophen as needed for knee pain. The diagnosis of adrenal insufficiency (AI) was considered. Serum cortisol level after adrenocorticotropin hormone (ACTH) stimulation was abnormal. Because her plasma ACTH level was not increased, a diagnosis of secondary AI (due to deficiency in ACTH) was made. Magnetic resonance imaging of the brain performed to exclude the presence of a sellar or suprasellar mass showed reduction in size of the pituitary gland and an increased cerebrospinal fluid content within the sella, consistent with a partially empty sella. The patient’s symptoms improved rapidly with hydrocortisone therapy but during follow-up, the dose of hydrocortisone was found to be excessive. Important differences exist between primary and secondary AI, and the diagnosis of secondary AI may be challenging. The therapy of AI should be carefully tailored to the requirements of the individual patient.

JAMA. 2005;294:2481-2488
www.jama.com

A 44-year-old woman reported several weeks of fatigue, somnolence, pain in the large joints, nausea, and decreased appetite. She had also noted an unintentional 11-kg weight loss over a period of 6 months. She had a remote history of amenorrhea, but she was presently menstruating regularly. She was taking no medications, with the exception of acetaminophen as needed for knee pain. The diagnosis of adrenal insufficiency (AI) was considered. Serum cortisol level after adrenocorticotropin hormone (ACTH) stimulation was abnormal. Because her plasma ACTH level was not increased, a diagnosis of secondary AI (due to deficiency in ACTH) was made. Magnetic resonance imaging of the brain performed to exclude the presence of a sellar or suprasellar mass showed reduction in size of the pituitary gland and an increased cerebrospinal fluid content within the sella, consistent with a partially empty sella. The patient’s symptoms improved rapidly with hydrocortisone therapy but during follow-up, the dose of hydrocortisone was found to be excessive. Important differences exist between primary and secondary AI, and the diagnosis of secondary AI may be challenging. The therapy of AI should be carefully tailored to the requirements of the individual patient.

See also Patient Page.

CME available online at www.jama.com

©2005 American Medical Association. All rights reserved.

(Reprinted) JAMA, November 16, 2005—Vol 294, No. 19 2481
ADRENAL INSUFFICIENCY

0.18-1.6 ng/dL [2.32-20.59 pmol/L], with a thyroid-stimulating hormone of 3.3 mIU/mL (normal range, 0.5-4.5 mIU/mL). An ACTH stimulation test was performed. Sixty minutes after the intravenous injection of 1 to 2 synthetic ACTH (250-µg intravenous), the serum cortisol was 7 µg/dL (normal, >18 µg/dL).

Magnetic resonance imaging of the brain, performed to exclude the presence of a sellar or suprasellar mass, showed reduction in size of the pituitary gland, mild leftward deviation of the pituitary stalk, and an increased cerebrospinal fluid content within the sella, consistent with a partially empty sella, but no tumor mass or cyst.

The patient started taking hydrocortisone (20 mg in the morning and 10 mg in the afternoon). Two months later, she reported significant improvement of all her symptoms and a 6-kg weight gain. Six months later she was feeling well, but her weight had increased to 94 kg (24.5 kg in 9 months of therapy; BMI, 34.1), with preferential accumulation of adipose tissue in her abdomen. Her hydrocortisone dose was reduced to 10 mg in morning and 5 mg in afternoon, without any relapse of her symptoms. Three and half years later, she was still doing well with the same hydrocortisone dose and her weight was 87 kg (BMI, 31.5). She was still having regular periods. The insulin-like growth factor 1 was low at 71 ng/mL (normal, 90-360 ng/mL).

DISCUSSION

This patient has symptoms and biochemical evidence of adrenal insufficiency (AI), as shown by her abnormal cortisol response to ACTH (the interpretation criteria of the ACTH stimulation test will be discussed below). Her AI is secondary to reduced ACTH secretion rather than due to a primary disease of the adrenal glands, as indicated by the inappropriately normal plasma ACTH level. The past history of amenorrhea is consistent with the possibility that the patient has a pituitary pathology, possibly a pituitary adenoma that infarcted, leaving an “empty sella.”

Although ACTH deficiency with normal thyroid-stimulating hormone and gonadotropin secretion (judged by the resumption and continuation of normal menses) is rare, it has been described before in a similar setting. The low serum insulin-like growth factor 1 in a patient with hypopituitarism strongly suggests growth hormone deficiency.

The etiology, diagnosis, and therapy of primary and secondary AI, as well as the differences between these 2 disease states, are reviewed herein. The major hormones of the hypothalamic-pituitary-adrenal (HPA) axis are shown in the Figure.

Classification of AI

Adrenal insufficiency develops when a large part of the function of the adrenal glands is lost. Primary AI is caused by processes that damage the adrenal glands or by drugs that block cortisol synthesis. In contrast, secondary AI results from processes that reduce the secretion of ACTH by the pituitary gland due to a pituitary or hypothalamic pathology; although the latter, due to deficit of corticotrophin-releasing hormone (CRH), is sometimes called tertiary AI. In this review, both forms are included in the secondary AI group. Both primary and secondary AI can develop either slowly, over several weeks or months, or acutely, with catastrophic consequences that may lead to cardiovascular collapse and death. The classification and common etiologies of primary and secondary AI are shown in the Figure.

Primary AI. In developed countries, the most frequent cause of primary AI is autoimmune adrenalitis. In the developing world, on the other hand, tuberculosis most likely remains the more common cause of adrenal failure. In young males, adrenal necrosis (or the less severe adrenomyeloneuropathy) must be considered. This disease, transmitted as a recessive X-linked trait, is due to the accumulation of very long chain fatty acyl-CoA intermediates in the adrenal glands and in the central nervous system. Therefore, the clinician should perform a careful neurological examination in young males with primary AI, keeping in mind that AI can appear long before neurological symptoms. Several infectious processes known to be associated with AIDS, particularly Cytomegalovirus, Mycobacterium tuberculosis, Cryptococcus neoformans, Toxoplasma gondii, Mycobacterium avium intracellulare, Pneumocystis jiroveci, and Histoplasma capsulatum, may lead to adrenal gland destruction. Among medications, ketoconazole (an antifungal) and etomidate (a general anesthetic) can cause AI.

Secondary AI. The most common cause of secondary AI is the abrupt discontinuation of long-term administration of glucocorticoids. There is a great individual variability in susceptibility to suppression of the HPA axis by exogenous glucocorticoids; therefore, the presence of AI cannot be predicted reliably by the dose and duration of glucocorticoid use. Several weeks of exogenous glucocorticoid administration are required for the development of AI. Intramuscular, intra-articular, and even inhaled or topical glucocorticoids can cause significant suppression of the HPA axis. Similarly, megestrol acetate, a synthetic progesterone used to increase appetite in a variety of cachexia-inducing illnesses, can suppress ACTH secretion at doses of more than 160 mg/d, leading to secondary AI.

Secondary AI can be caused by pituitary adenomas, carcinopharyngiomas, pituitary surgery, lymphocytic hypophysitis, and a wide variety of other neoplastic, inflammatory, and infectious processes involving the sellar or suprasellar area. Pituitary or whole brain irradiation can cause AI up to several years after its completion. Finally, traumatic brain injury and subarachnoid hemorrhage can cause AI that may not manifest itself until several months after the acute event.

In the failing pituitary gland, ACTH secretion is usually the last function to
be lost. As the present case illustrates, however, exceptions to this rule occur. The patient had ACTH deficiency (and possibly growth hormone deficiency) despite the presence of normal thyroid and gonadotropin function. Such exceptions are more frequent in postirradiation hypopituitarism.13

Clinical Presentation
The development of acute AI is potentially lethal. The physician must consider AI as a possible cause of unexplained deterioration of cardiovascular status. Adrenal hemorrhage or infarction occurs in patients who are severely ill from underlying conditions, including sepsis, pulmonary embolism, acute renal failure, acute myocardial infarction, and heart failure.15,16 The presence of antiphospholipid antibodies or pharmacological anticoagulation can lead to adrenal hemorrhage or infarction.17

Patients with slow onset AI usually complain of being chronically fatigued. They often report joint pain, lack of appetite, unintentional weight loss, abdominal pain, nausea, and diarrhea. Primary AI, in contrast with secondary AI, is often associated with lack of aldosterone as well as cortisol. Consequently, symptoms and signs of mineralocorticoid deficiency (salt-craving, postural hypotension, electrolyte abnormalities) usually indicate primary AI. For any given level of morning serum cortisol, patients with primary AI have more severe symptoms than patients with secondary AI.18 Patients with secondary AI are often able to function relatively well during unstressed periods, and they may manifest cardiovascular instability or hypoglycemia only when they undergo physical stress.

Hyperpigmentation of the skin and of the mucosae resulting from the melanocyte-stimulating activity of β lipotropin, which derives from the same precursor as ACTH, is observed only in primary AI. Although hyperkalemia is observed only in primary AI, hypotension can also occur in secondary AI, as the result of reduced glomerular fil-
tration rate, increased antidiuretic hormone secretion, and possible concomitant central hypothyroidism. Patients with primary AI caused by autoimmune adrenalitis are at risk for other manifestations of autoimmune disease, such as vitiligo. Hashimoto thyroiditis, pernicious anemia, and type 1 diabetes mellitus. Table 1 illustrates some of the contrasts between primary and secondary AI.

Diagnosis of AI
Once AI is suspected, a variety of tests may be used to evaluate adrenal function. A stepwise approach helps maintain cost-effectiveness in screening all the patients in whom this potentially dangerous (and treatable) disease is suspected.

Nonstimulated Serum Cortisol. The initial test in an ambulatory patient should be a 6- to 8-AM measurement of serum cortisol and plasma ACTH. This approach exploits the fact that serum cortisol level peaks in the early morning hours. A careful social and work history should be obtained before ordering this test, as shift workers or patients with unusual sleep-wake patterns may have altered cortisol circadian rhythm. This test is helpful if the serum cortisol level is more than 18 µg/dL (normal adrenal function) or less than 3 µg/dL (indicates AI). In the latter case, plasma ACTH level will distinguish between primary and secondary AI. In primary AI, the ACTH level is almost invariably more than 100 pg/mL, while in secondary AI, plasma ACTH can be either low or inappropriately normal (when serum cortisol is reduced).

In patients with severe physical stress, serum cortisol level should be more than 18 µg/dL at any time of the day. One exception is the patient with severe hypothryroidism, because albumin and cortisol-binding globulin normally bind approximately 90% of circulating serum cortisol. In patients who are severely ill with serum albumin values of less than 2.5 g/L, the total cortisol is often markedly lower than 18 µg/dL; however, the free fraction of cortisol may be normal. In such patients, the total serum cortisol is less reliable than free cortisol as an index of AI. Unfortunately, direct measurement of free serum cortisol is not yet widely available, and there is no formula to correct serum cortisol according to albumin or total protein level. For this reason, patients diagnosed with AI in the intensive care unit based on serum cortisol should be retested in the outpatient setting before being committed to a life-long glucocorticoid treatment.

If an ambulatory patient has a morning serum cortisol level of between 3.1 and 17.9 µg/dL, some sort of dynamic test of adrenal function is essential. The test options for the assessment of adrenal function are summarized in Table 2. None of the available stimulation tests is ideal in terms of sensitivity and specificity. Consequently, the test results must be interpreted in the context of the clinical scenario. The choice of the test depends on several factors, including the experience of the physician and practical considerations related to test performance.

Insulin-Induced Hypoglycemia (Insulin Tolerance Test). The insulin tolerance test (ITT) measures the patient’s cortisol response to hypoglycemia induced by the intravenous administration of insulin. This test is often considered the criterion standard because it assesses the ability of the entire HPA axis to respond to the stressful situation of hypoglycemia. Following insulin (0.1 IU/kg) administration, blood is drawn during symptomatic hypoglycemia (glucose should decrease to less than 40 mg/dL).

Table 1. Signs and Symptoms of Primary and Secondary Adrenal Insufficiency (AI)

<table>
<thead>
<tr>
<th>Primary AI</th>
<th>Secondary AI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and mucosae</td>
<td>Pale</td>
</tr>
<tr>
<td>Sodium</td>
<td>Low</td>
</tr>
<tr>
<td>Associated diseases</td>
<td>Primary hypothyroidism, type 1 diabetes mellitus, vitiligo, neurological deficit (adrenoleukodystrophy, males only)</td>
</tr>
<tr>
<td>Associated diseases</td>
<td>Central hypogonadism or hypothryroidism, growth hormone deficiency, diabetes insipidus, headaches, visual abnormalities</td>
</tr>
</tbody>
</table>

Table 2. Synopsis of the Dynamic Tests Available to Assess Adrenal Function

<table>
<thead>
<tr>
<th>Test</th>
<th>ITT</th>
<th>Metyrapone</th>
<th>CRH</th>
<th>Conventional-Dose ACTH</th>
<th>Low-Dose ACTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stimulus</td>
<td>Insulin, 0.1-0.15 IU/kg intravenously</td>
<td>Metyrapone, 30 mg/kg by mouth at midnight (maximum, 3300 mg)</td>
<td>Ovine CRH, 1 µg/kg intravenously</td>
<td>1-24 ACTH, 250 µg intravenously (or intramuscularly)</td>
<td>1-24 ACTH, 1 µg intravenously</td>
</tr>
<tr>
<td>Blood drawing time points</td>
<td>30, 45, 60, and 90 min</td>
<td>8 AM following morning</td>
<td>15, 30, and 60 min</td>
<td>30 or 60 min</td>
<td>30 min</td>
</tr>
<tr>
<td>Measurements</td>
<td>Serum cortisol, blood glucose</td>
<td>Serum cortisol and 11-deoxycortisol</td>
<td>Serum cortisol</td>
<td>Serum cortisol</td>
<td>Serum cortisol</td>
</tr>
<tr>
<td>Cutoff</td>
<td>Serum cortisol &gt;18 µg/dL, if glucose decreased &lt;40 mg/dL</td>
<td>Serum 11-deoxycortisol &gt;7 µg/dL, with serum cortisol &lt;5 µg/dL</td>
<td>Serum cortisol &gt;18.5 µg/dL</td>
<td>Serum cortisol &gt;18 µg/dL</td>
<td>Serum cortisol &gt;18 µg/dL</td>
</tr>
</tbody>
</table>

Abbreviations: ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; ITT, insulin tolerance test. SI conversion: To convert glucose to mmol/L, multiply by 0.0555.
than 40 mg/dL (<2.22 mmol/L). In obese patients with insulin resistance, the usual dose of insulin should be increased to 0.15 IU/kg. A serum cortisol peak of more than 18 µg/dL is considered normal. The ITT has the advantage that it can also test the growth hormone reserve in patients with pituitary or hypothalamic disease. It is contraindicated in patients older than 60 years, and in those with history of seizures, or with documented or suspected coronary artery disease. It requires close medical supervision and trained personnel. Even the ITT has some limitations in terms of reproducibility and clear cutoff levels. It has been proposed that to improve its specificity glucose should decrease to less than 5 mmol/L, with accompanying potential higher risks.

Metyrapone Test. The metyrapone test measures the ability of the HPA axis to respond to an acute reduction in serum cortisol levels. Metyrapone inhibits 11-hydroxylase, the enzyme involved in the last step of cortisol synthesis. This inhibition causes a decrease in cortisol that results (in a healthy patient) in a compensatory increase in ACTH and in the cortisol precursor, 11-deoxycortisol. This test is simple, relatively inexpensive, very sensitive, and requires a single blood drawing. The administration of metyrapone (30 mg/kg; maximal dose, 3000 mg) occurs at midnight, and blood is drawn the following morning at 8 AM for cortisol and 11-deoxycortisol. In response to metyrapone, serum cortisol level should decrease to less than 5 µg/dL, and 11-deoxycortisol should increase to more than 7 µg/dL. Recently, it has been proposed that the sum of cortisol and 11-deoxycortisol should be more than 16.5 µg/dL. Although some authors recommend that this test should be performed only during a hospital admission, a large retrospective series found it to be safe and suitable for the outpatient setting. Regrettably, the intermittent availability of metyrapone limits its applicability in the United States.

CRH Stimulation Test. The CRH stimulation test measures the ability of the pituitary gland to secrete ACTH in response to CRH and the ability of the adrenal gland to respond with an increase in cortisol to the increase in circulating ACTH. Ovine CRH (1 µg/kg) is injected intravenously, and cortisol is measured after 15, 30, and 60 minutes. The test has been proposed as a way to differentiate secondary (pituitary disease) from tertiary (hypothalamic disease) AI. However, a serum cortisol cutoff that allows high specificity (18.5 µg/dL) is faulted by very low sensitivity (33%). The lack of multiple studies involving large numbers of patients and the high cost of CRH have greatly limited its use.

ACTH Stimulation Test. The ACTH stimulation test is based on the inability of a diseased adrenal gland to respond acutely to the injection of ACTH by secreting cortisol. In the conventional ACTH stimulation test, 250 µg of synthetic (1-24) ACTH is injected intravenously (or intramuscularly), and serum cortisol levels are measured at 30 or 60 minutes. A serum cortisol level of more than 18 µg/dL at either time point constitutes a normal response, independent of baseline level and time of day. Although some healthy individuals can peak below this cutoff level, a peak of less than 15 µg/dL is invariably abnormal.

The choice of the 250-µg dose is based solely on the fact that ACTH comes in 250-µg vials. However, with this dose, ACTH reaches plasma levels that are approximately 1000 times the values observed in maximally stressed healthy individuals, thereby potentially causing a falsely normal cortisol response by an adrenal gland that is in fact partially impaired. Based on this observation, Dickstein et al proposed the use of a more physiological low ACTH dose (1 µg) to identify milder forms of secondary AI. They showed that in healthy individuals, the 1-µg dose causes a similar increase in serum cortisol at 30 minutes, with a decline at 60 minutes. Because ACTH is packaged only in 250-µg vials, it must be diluted to reach lower concentrations (ie, 1 µg/mL), and it can be kept at 4°C for up to 4 months without any decline in biological activity.

In several studies, the low-dose ACTH stimulation test has been shown to be more sensitive for diagnosing mild secondary AI than the traditional 250-µg test, but not as sensitive as the ITT or metyrapone tests. However, a recent meta-analysis has found the sensitivity and specificity of the 2 tests to be not significantly different in the diagnosis of secondary AI. Both doses perform equally well for the diagnosis of primary AI, even in mild cases. Using the low-dose test, most authors recommend using a 30-minute serum cortisol cutoff of 18 µg/dL. When the results of this test are borderline (peak serum cortisol between 15 and 18 µg/dL), confirmation by either the metyrapone test or ITT should be performed.

There are sporadic reports of possible dangers of missing the diagnosis of secondary AI using the 250-µg test. However, it has not yet been proven in a large cohort whether patients who pass the high-dose test but fail the low-dose test actually benefit from glucocorticoid therapy.

As long-term reduction in ACTH secretion is needed to develop adrenal atrophy, any form of ACTH stimulation test generates false-negative results in patients with a recent onset of ACTH deficiency, such as those who have recently undergone pituitary surgery or had a pituitary infarction. The reduction in ACTH secretion must be chronic (>1 month) and probably severe to cause atrophy of the adrenal glands. Because the low-dose test is simple to perform, potentially more sensitive than the high-dose test, and less expensive (many patients can be tested with a single 250-µg ACTH vial), it should be the routine procedure used in the evaluation of potential cases of both primary and secondary AI.

Identifying the Cause of AI

Once the diagnosis of AI is established, the physician must determine its cause.
In primary AI, the age of the patient, associated morbidities, clinical picture, and medical history must guide the decisions regarding work-up. Measurement of anti-adrenal antibodies may help the diagnosis of autoimmune adrenitis. This test is highly specific but not 100% sensitive.39 Measurement of very long chain fatty acids must be obtained if adrenoleukodystrophy is suspected. Computed tomography imaging of the adrenals may unveil hemorrhagic, metastatic, or infectious diseases. Adrenal biopsy may occasionally be needed. In secondary AI, in the absence of a history of exogenous glucocorticoid exposure, magnetic resonance imaging of the sellar region is mandatory, as secondary AI may be the presenting feature of a neoplastic process in the pituitary or the hypothalamus.

**Therapy**

**Glucocorticoids.** Glucocorticoids are the main therapy for all forms of AI. Although several kinds of glucocorticoids can be used, hydrocortisone (10-12.5 mg/m² per day) is preferred because its short half-life mimics most closely the normal cortisol circadian rhythm. This dose of hydrocortisone is not associated with reduced bone mineral density.39 The downside is that hydrocortisone must be given twice or 3 times a day.40 The classic dose of 30 mg/d (20 mg in the morning and 10 mg in the afternoon) is probably excessive in most patients, particularly patients with secondary AI, as shown by today's patient, who gained a significant amount of weight with this dose. Other glucocorticoids may be administered, keeping in mind their potencies relative to that of hydrocortisone (Table 3).9,41 Long-acting glucocorticoids are preferred when, together with replacement therapy, one wants to suppress ACTH secretion, such as in congenital adrenal hyperplasia.

Because there is no good biochemical index to help determine the right glucocorticoid dose to reduce long-term adverse effects on bone and other tissues, the smallest amount that improves the patient's symptoms is recommended.32 In patients with glucocorticoid-induced AI, using a small dose may accelerate the recovery of the HPA axis.9 In some patients who have mild secondary AI and no symptoms during everyday life, hydrocortisone may be required only during periods of physical stress. In contrast with the approach to treating primary hypothyroidism, when restoration of a normal thyroid-stimulating hormone is an important target of therapy, in the treatment of primary AI, attempting to normalize plasma ACTH levels is not recommended because this invariably results in overdosing and the induction of an iatrogenic Cushing syndrome state.31 In patients who are also hypothyroid, thyroid hormones should never be replaced before administering glucocorticoids; euthyroidism may trigger an adrenal crisis by accelerating the metabolism of cortisol. Similarly, growth hormone therapy can accelerate cortisol metabolism, thereby requiring adjustment of hydrocortisone dosing.44

The cytochrome P450 CYP3A4 isozyme is involved in the hepatic metabolism of glucocorticoids. Therefore, patients who are taking drugs that may increase (phenytoin, rifampin, barbiturates) or decrease (protease inhibitors) the function of this enzyme may need higher or lower doses of glucocorticoids, respectively.45,46 In patients who are taking protease inhibitors, significant adrenal suppression may occur within few months of therapy with inhaled steroids.37

Women usually do not need adjustment in their dose of glucocorticoids during pregnancy, but in case of protracted first trimester vomiting, parenteral administration may be needed. Every patient with AI should wear a medical alert bracelet or necklace stating the need for glucocorticoids in case of an emergency. An emergency glucocorticoids injection kit should be prescribed to patients who live or travel to remote areas, where they may not have readily available medical assistance.

**Mineralocorticoids.** Patients with primary AI also need mineralocorticoid therapy. The only drug available is fludrocortisone. Its dose ranges in most cases between 0.05 and 0.2 mg/d, usually in a single dose. The dose is adjusted according to the patient's symptoms, including orthostatic dizziness and salt craving, and to serum potassium and plasma renin activity. Suppressed plasma renin activity is a useful marker of fludrocortisone overdose. In the absence of orthostatic symptoms or of significant changes in the blood pressure or heart rate during orthostatic maneuvers, however, the fludrocortisone dose should not be increased even if the plasma renin activity is increased to mild or moderate levels. Overdosing of fludrocortisone can cause fluid retention, edema, and hypertension.

**Androgen.** In women with AI, dehydroepiandrosterone replacement improves well-being and sexuality.47 As dehydroepiandrosterone is considered a dietary supplement in the United States, it is not regulated by the US Food and Drug Administration. Arlt et al48 showed that patients treated with 50 mg/d dehydroepiandrosterone increase their serum dehydroepiandrosterone-sulfate and testosterone levels; therefore, these measurements can be used to determine adequateness of the supplement and the patient's adherence.
Therapy During Stress. During illnesses, the glucocorticoid dose should be increased. One reasonable approach is to double the maintenance dose in the setting of fevers (temperatures >38°C), major dental procedures (tooth extractions or root canals), or invasive diagnostic procedures (gastroscopy, colonoscopy, cystoscopy, or bronchoscopy). Patients with AI are more likely to develop cardiovascular instability when they have a disease that causes vomiting or diarrhea. In these situations, in addition to the increased glucocorticoid requirement, they may not properly absorb the oral therapy. For this reason, patients with AI should go the emergency department if they experience multiple episodes of vomiting and/or diarrhea.

The glucocorticoid doses commonly used during major stress (major surgery, severe infection, myocardial infarction)—80 to 100 mg of hydrocortisone every 8 hours—are probably excessive.81 Therefore, the maximal dose recommended is 50 mg of hydrocortisone every 8 hours. When such a dose is administered, there is no need to prescribe fludrocortisone even in patients with primary AI, because the high doses of hydrocortisone will activate the mineralocorticoid receptor. It is possible that even this dosage is excessive in patients with secondary AI. A small study82 showed that among patients with glucocorticoid-induced AI (taking a mean daily prednisone dose of 18.8 mg) undergoing major surgery, a group treated with the usual prednisone dose and a group that received stress-dose glucocorticoids had no difference in perioperative complications.

Patients with septic shock whose total serum cortisol increases by less than 9 μg/dL in response to 250 μg of ACTH have lower mortality when treated with hydrocortisone (50 mg every 6 hours) plus fludrocortisone (0.05 mg/d).83 This benefit is likely a pharmacological effect and does not necessarily classify these patients as having AI.

CONCLUSION
The symptoms of AI are nonspecific and this disease often goes undiagnosed for extended periods of time, with the risk of potential serious consequences. Therefore, physicians must suspect it in the presence of the symptoms described earlier, particularly in patients with a history of autoimmune diseases or signs or symptoms consistent with hypopituitarism. The work-up must be step-wise and should start from the least expensive test (morning serum cortisol). Adrenal insufficiency needs to be suspected in severely ill patients with cardiovascular instability. In this setting, glucocorticoids should be administered empirically while waiting for the results of a pretreatment serum cortisol.

Confirming the diagnosis of partial secondary AI may be challenging and repeated testing may be needed before committing a patient to a lifelong glucocorticoid therapy. As both lack of needed treatment and not warranted glucocorticoids are dangerous, in dubious cases the decision of whether to treat a patient with suspected AI should be left to practitioners who have experience in the field. Glucocorticoids need to be prescribed judiciously, using the lowest possible dose that improves the patient’s symptoms to avoid long-term adverse effects on bone, blood pressure, body composition, and glucose metabolism.

Financial Disclosures: None reported.

Acknowledgment: I thank John Stone, MD, and Simeon Margolis, MD, PhD, from the Department of Medicine, Johns Hopkins University, for critically reviewing the manuscript. No compensation was given to either of them.

REFERENCES
5. Kestelimir F. The endocrinology of adrenal tuberculo-culosis: the effects of tuberculin on the hypothalamo-

ADRENAL INSUFFICIENCY

©2005 American Medical Association. All rights reserved.


